Archive: Company News
New investigator-initiated clinical trials of BellaSeno´s resorbable tissue regeneration scaffolds to be conducted in Europe
— New clinical trial site opened in Italy for pectus excavatum and planned in Germany for bone reconstruction
— Company aims to expand EU market authorization from custom-made to off-the-shelf products and and to pursue market approval in the USA
BellaSeno GmbH, an ISO 13485-certified medtech company developing resorbable scaffolds using additive manufacturing technologies, today announced that additional, investigator-initiated clinical trials of its novel regenerative scaffolds for bone reconstruction and chest-wall defects (pectus excavatum) will be conducted in Germany and Italy, respectively. In 2023, BellaSeno had received market authorization for its custom-made, resorbable bone and pectus excavatum scaffolds in Europe.
selectION, Inc. to Present Update on Clinical Progress at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on January 11, 2024
— Best-in-class Kv1.3 blocker has successfully completed a Phase 1b trial in atopic dermatitis patients
— Pipeline molecule to treat T cell mediated autoimmune diseases
selectION, Inc., a clinical-stage biopharmaceutical company developing novel treatments for T cell mediated autoimmune diseases, today announced that management will present at the 42nd Annual J.P. Morgan Healthcare Conference. The presentation will be held Thursday, January 11, 2024, 08:00 AM – 08:25 AM PST at Golden Gate (32nd Floor), The Westin.
1ST Biotherapeutics, Inc. Announces First Patient Dosed in Phase I/II Study of HPK1 Inhibitor FB849 in Patients with Advanced Solid Tumors
1ST Biotherapeutics, Inc., a clinical-stage biotechnology company focused on the development of novel small molecule therapeutics in neurodegenerative diseases, immuno-oncology, and rare diseases, today announced the first patient dosing in the clinical Phase I/II trial evaluating FB849 in patients with advanced solid tumors.